223 related articles for article (PubMed ID: 28449044)
1. Vernakalant does not alter early repolarization or contractility in normal and electrically remodelled atria.
van Hunnik A; Nasrallah H; Lau DH; Kuiper M; Verheule S; Schotten U
Europace; 2018 Jan; 20(1):140-148. PubMed ID: 28449044
[TBL] [Abstract][Full Text] [Related]
2. Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness.
van Hunnik A; Lau DH; Zeemering S; Kuiper M; Verheule S; Schotten U
Heart Rhythm; 2016 Apr; 13(4):964-72. PubMed ID: 26681610
[TBL] [Abstract][Full Text] [Related]
3. Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.
Burashnikov A; Pourrier M; Gibson JK; Lynch JJ; Antzelevitch C
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):400-8. PubMed ID: 22322366
[TBL] [Abstract][Full Text] [Related]
4. Analysis of electropharmacological effects of AVE0118 on the atria of chronic atrioventricular block dogs: characterization of anti-atrial fibrillatory action by atrial repolarization-delaying agent.
Kambayashi R; Hagiwara-Nagasawa M; Ichikawa T; Goto A; Chiba K; Nunoi Y; Izumi-Nakaseko H; Matsumoto A; Takahara A; Sugiyama A
Heart Vessels; 2020 Sep; 35(9):1316-1322. PubMed ID: 32346771
[TBL] [Abstract][Full Text] [Related]
5. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
[TBL] [Abstract][Full Text] [Related]
6. Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs.
Bechard J; Gibson JK; Killingsworth CR; Wheeler JJ; Schneidkraut MJ; Huang J; Ideker RE; McAfee DA
J Cardiovasc Pharmacol; 2011 Mar; 57(3):302-7. PubMed ID: 21266917
[TBL] [Abstract][Full Text] [Related]
7. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.
Burashnikov A; Barajas-Martinez H; Hu D; Robinson VM; Grunnet M; Antzelevitch C
J Cardiovasc Pharmacol; 2020 Aug; 76(2):164-172. PubMed ID: 32453071
[TBL] [Abstract][Full Text] [Related]
8. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat.
de Haan S; Greiser M; Harks E; Blaauw Y; van Hunnik A; Verheule S; Allessie M; Schotten U
Circulation; 2006 Sep; 114(12):1234-42. PubMed ID: 16940189
[TBL] [Abstract][Full Text] [Related]
9. Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.
Frommeyer G; Ellermann C; Dechering DG; Kochhäuser S; Bögeholz N; Güner F; Leitz P; Pott C; Eckardt L
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1214-1219. PubMed ID: 27283775
[TBL] [Abstract][Full Text] [Related]
10. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs.
Wirth KJ; Paehler T; Rosenstein B; Knobloch K; Maier T; Frenzel J; Brendel J; Busch AE; Bleich M
Cardiovasc Res; 2003 Nov; 60(2):298-306. PubMed ID: 14613859
[TBL] [Abstract][Full Text] [Related]
11. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.
Burashnikov A; Barajas-Martinez H; Hu D; Nof E; Blazek J; Antzelevitch C
J Cardiovasc Pharmacol; 2012 Jun; 59(6):539-46. PubMed ID: 22370957
[TBL] [Abstract][Full Text] [Related]
12. Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca
Diness JG; Skibsbye L; Simó-Vicens R; Santos JL; Lundegaard P; Citerni C; Sauter DRP; Bomholtz SH; Svendsen JH; Olesen SP; Sørensen US; Jespersen T; Grunnet M; Bentzen BH
Circ Arrhythm Electrophysiol; 2017 Oct; 10(10):e005125. PubMed ID: 29018164
[TBL] [Abstract][Full Text] [Related]
13. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.
Blaauw Y; Gögelein H; Tieleman RG; van Hunnik A; Schotten U; Allessie MA
Circulation; 2004 Sep; 110(13):1717-24. PubMed ID: 15364815
[TBL] [Abstract][Full Text] [Related]
14. I
Hou JW; Li W; Fei YD; Chen YH; Wang Q; Wang YP; Li YG
J Physiol Biochem; 2018 Feb; 74(1):57-67. PubMed ID: 29243206
[TBL] [Abstract][Full Text] [Related]
15. Vernakalant: A novel agent for the termination of atrial fibrillation.
Finnin M
Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
Tsuji Y; Dobrev D
Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
[TBL] [Abstract][Full Text] [Related]
17. Effects of potassium channel blockers on changes in refractoriness of atrial cardiomyocytes induced by stretch.
Qi J; Xiao J; Zhang Y; Li J; Liu Y; Li P; Liang L; Jiang B; Wen W; Zhao C; Liang D; Liu Y; Chen YH
Exp Biol Med (Maywood); 2009 Jul; 234(7):779-84. PubMed ID: 19429854
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts.
van Middendorp LB; Strik M; Houthuizen P; Kuiper M; Maessen JG; Auricchio A; Prinzen FW
Europace; 2014 Aug; 16(8):1249-56. PubMed ID: 24481779
[TBL] [Abstract][Full Text] [Related]
19. Late Sodium Current in Atrial Cardiomyocytes Contributes to the Induced and Spontaneous Atrial Fibrillation in Rabbit Hearts.
Chu Y; Yang Q; Ren L; Yu S; Liu Z; Chen Y; Wei X; Huang S; Song L; Zhang P; Ma J; Wu L
J Cardiovasc Pharmacol; 2020 Oct; 76(4):437-444. PubMed ID: 32675747
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization.
Frommeyer G; Milberg P; Clauss C; Schmidt M; Ramtin S; Kaese S; Grundmann F; Grotthoff JS; Pott C; Eckardt L
Europace; 2014 Aug; 16(8):1240-8. PubMed ID: 24696223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
